{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:12:12Z","timestamp":1789215132039,"version":"build-2803163510"},"reference-count":13,"publisher":"Touch Medical Media, Ltd.","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<p>\n                    Pancreatic neuroendocrine tumours (pNETs) are a major manifestation of multiple endocrine neoplasia type 1 (MEN1), and the most significant cause of morbidity and mortality in this disorder. There is some evidence that the early use of somatostatin analogues can retard progression, especially of small non-functioning tumours, but there are no other prophylactic therapies for patients, and the treatment of metastatic disease is similar to that for sporadic pNETs. A recent study has shown that in cell line and animal models,\n                    <italic>MEN1<\/italic>\n                    mutations lead to an upregulation of the enzyme dihydroorotate dehydrogenase (DHODH), which is involved in increasing precursor metabolites for the synthesis of pyrimidines. In these studies, blockade of this pathway by various means, including the DHODH inhibitor leflunomide, attenuates cell growth and tumour progression, suggesting a critical dependence on DHODH specifically in\n                    <italic>MEN1<\/italic>\n                    -mutated tissue. Preliminary clinical studies in three patients with MEN1 and pNETs have indicated some therapeutic potential of this drug, which has previously been used for some years in patients with rheumatoid arthritis. It is suggested that further clinical trials of this re-purposed drug are indicated to evaluate its potential for the treatment of patients with MEN1 and pNETS. This article describes the clinical problem of MEN1 and pNETs, and reviews the recent publication reporting on these initial results.\n                  <\/p>","DOI":"10.17925\/ee.2022.18.2.86","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T12:39:09Z","timestamp":1670416749000},"page":"86","source":"Crossref","is-referenced-by-count":5,"title":["A New Medical Therapy for Multiple Endocrine Neoplasia Type 1?"],"prefix":"10.17925","volume":"18","author":[{"given":"Hessa","family":"Boharoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, UK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Grossman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, UK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Thakker RV, Newey PJ, Walls GV, et al. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).\n                      J Clin Endocrinol Metab\n                      . 2012;97:2990\u20133011.","DOI":"10.1210\/jc.2012-1230"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Brandi ML, Agarwal SK, Perrier ND, et al. Multiple endocrine neoplasia type 1: Latest insights.\n                      Endocr Rev\n                      . 2021;42:133\u201370.","DOI":"10.1210\/endrev\/bnaa031"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Falconi M, Eriksson B, Kaltsas G, et al.; Vienna Consensus Conference participants. ENETS Consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.\n                      Neuroendocrinology\n                      . 2016;103:153\u201371.","DOI":"10.1159\/000443171"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Challis BG, Casey RT, Grossman A, et al. What is the appropriate management of non-functioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?\n                      Clin Endocrinol (Oxf)\n                      . 2019;91;708\u201315.","DOI":"10.1111\/cen.14094"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Giudici F, Cavalli T, Giusti F, et al. Natural History of MEN1 GEPNET: Single-center experience after a long follow-up.\n                      World J Surg\n                      . 2017;41:2312\u201323.","DOI":"10.1007\/s00268-017-4019-2"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas.\n                      Ann Surg\n                      . 2006;243:265\u201372.","DOI":"10.1097\/01.sla.0000197715.96762.68"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Lopez CL, Joos B, Bartsch DK, et al. Chemoprevention with Somatuline\n                      \u00a9\n                      delays the progression of pancreatic neuroendocrine neoplasms in a mouse model of multiple endocrine neoplasia type 1 (MEN1).\n                      World J Surg\n                      . 2019;43:831\u20138.","DOI":"10.1007\/s00268-018-4839-8"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ramundo V, Del Prete M, Marotta V, et al.; Multidisciplinary Group for Neuroendocrine Tumors of Naples. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.\n                      Clin Endocrinol (Oxf)\n                      . 2014;80:850\u20135.","DOI":"10.1111\/cen.12411"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Faggiano A, Modica R, Lo Calzo F, et al. Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimeters.\n                      J Clin Endocrinol Metab\n                      . 2020;105:78\u201384.","DOI":"10.1210\/clinem\/dgz007"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ma Y, Zhu Q, Wang X, et al. Synthetic lethal screening identifies DHODH as a target for MEN-mutated tumor cells.\n                      Cell Res\n                      . 2022;32:596\u20139.","DOI":"10.1038\/s41422-022-00613-1"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ng SB, Buckingham KJ, Lee C, et al. Exome sequencing identifies the cause of a Mendelian disorder.\n                      Nat Genet\n                      . 2010;42:30\u20135.","DOI":"10.1038\/ng.499"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Zhang C, Chu M. Leflunomide: A promising drug with good antitumor potential.\n                      Biochem Biophys Res Commun\n                      . 2018;496:726\u201330.","DOI":"10.1016\/j.bbrc.2018.01.107"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Clarke TL, Mostoslavsky R. DNA repair as a shared hallmark in cancer and ageing.\n                      Mol Oncol\n                      . 2022;Online ahead of print. doi: 10.1002\/1878-0261.13285.","DOI":"10.1002\/1878-0261.13285"}],"container-title":["European Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/endocrine-oncology\/journal-articles\/a-new-medical-therapy-for-multiple-endocrine-neoplasia-type-1\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:34Z","timestamp":1764745174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/endocrine-oncology\/journal-articles\/a-new-medical-therapy-for-multiple-endocrine-neoplasia-type-1\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"alternative-id":["EE.2022.18.2.86"],"URL":"https:\/\/doi.org\/10.17925\/ee.2022.18.2.86","relation":{},"ISSN":["1758-3772"],"issn-type":[{"value":"1758-3772","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}